Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 2. Kaplan-Meier plots for PFS and OS of 37 patients according to histological diagnosis (A and D), the extent of tumor resection (B and E), and adjuvant.

Published byRegina Wood Modified over 5 years ago

Similar presentations

Presentation on theme: "Fig. 2. Kaplan-Meier plots for PFS and OS of 37 patients according to histological diagnosis (A and D), the extent of tumor resection (B and E), and adjuvant."— Presentation transcript:

1 Fig. 2. Kaplan-Meier plots for PFS and OS of 37 patients according to histological diagnosis (A and D), the extent of tumor resection (B and E), and adjuvant therapy (C and F). PFS, progression-free survival; OS, overall survival; GTR, gross total resection; STR, subtotal resection; PA, partial resection; GBL, glioblastoma, IDH-wildtype; AA, anaplastic astrocytoma, IDH-wildtype; DMG, diffuse midline glioma, H3 K27M-mutant; CNS, central nervous system; PA, pilocytic astrocytoma. Fig. 2. Kaplan-Meier plots for PFS and OS of 37 patients according to histological diagnosis (A and D), the extent of tumor resection (B and E), and adjuvant therapy (C and F). PFS, progression-free survival; OS, overall survival; GTR, gross total resection; STR, subtotal resection; PA, partial resection; GBL, glioblastoma,… Brain Tumor Res Treat Oct;6(2):

Download ppt "Fig. 2. Kaplan-Meier plots for PFS and OS of 37 patients according to histological diagnosis (A and D), the extent of tumor resection (B and E), and adjuvant."

Similar presentations

Fig 2.1B: Axial T1 Weighted (Wtd.) MRIFig 2.1A: Axial Flair MRIFig 2.1C: Post-Contrast Axial T1 Wtd. MRI Fig 2.1D: Post Contrast Coronal T1 Wtd. MRIFig.

Fig 2.1B: Axial T1 Weighted (Wtd.) MRIFig 2.1A: Axial Flair MRIFig 2.1C: Post-Contrast Axial T1 Wtd. MRI Fig 2.1D: Post Contrast Coronal T1 Wtd. MRIFig.
Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial From.

Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC randomised trial From.
Supplementary Table S1. Patient demographics of the RRBS discovery set. Characteristics RRBS discovery set TotalIDH1/2 WT IDH1 MUT No. of Patients311120.

Supplementary Table S1. Patient demographics of the RRBS discovery set. Characteristics RRBS discovery set TotalIDH1/2 WT IDH1 MUT No. of Patients
Brain Tumors 2.21.16 Mark Browning, M.D. IUSME. Differential Diagnosis includes: Primary CNS tumor Most common primary sites of brain mets: – Lung – Breast.

Brain Tumors Mark Browning, M.D. IUSME. Differential Diagnosis includes: Primary CNS tumor Most common primary sites of brain mets: – Lung – Breast.
Marker SFRP1 SFRP2 SFRP5 DKK3 WIF1 APC CDH1 Unmethylated Methylated A

Marker SFRP1 SFRP2 SFRP5 DKK3 WIF1 APC CDH1 Unmethylated Methylated A
Astrocytomas Stud. Francesca Ochea, Carol Davila University of Medicine and Pharmacy Coord. assoc. prof. dr. Ligia Tataranu, Bagdasar-Arseni Emergency.

Astrocytomas Stud. Francesca Ochea, Carol Davila University of Medicine and Pharmacy Coord. assoc. prof. dr. Ligia Tataranu, Bagdasar-Arseni Emergency.
Volume 155, Issue 3, Pages (March 1996)

Volume 155, Issue 3, Pages (March 1996)
Fig. 3. Kaplan-Meier analyses of biochemical recurrence (BCR)-free survival rates according to ADCmeanvalues among the total subjects (A) and among the.

Fig. 3. Kaplan-Meier analyses of biochemical recurrence (BCR)-free survival rates according to ADCmeanvalues among the total subjects (A) and among the.
UK Renal Registry 10th Annual Report 2007

UK Renal Registry 10th Annual Report 2007
INCIDENCE AND SURVIVAL OF CENTRAL NERVOUS SYSTEM MALIGNANCIES ACCORDING TO HISTOLOGICAL SUBTYPES. RESULTS OF A POPULATION-BASED STUDY IN GIRONA (SPAIN)

INCIDENCE AND SURVIVAL OF CENTRAL NERVOUS SYSTEM MALIGNANCIES ACCORDING TO HISTOLOGICAL SUBTYPES. RESULTS OF A POPULATION-BASED STUDY IN GIRONA (SPAIN)
Oncol Res Treat 2016;39: DOI: /

Oncol Res Treat 2016;39: DOI: /
Figure 1. Progression-free survival and overall survival for FL/DLBCL patients. From: Clinicobiological features and prognostic impact of diffuse large.

Figure 1. Progression-free survival and overall survival for FL/DLBCL patients. From: Clinicobiological features and prognostic impact of diffuse large.
Figure 4 Progression-free survival, according to treatment group

Figure 4 Progression-free survival, according to treatment group
Improved outcome in central nervous system aspergillosis, using voriconazole treatment by Stefan Schwartz, Markus Ruhnke, Patricia Ribaud, Lawrence Corey,

Improved outcome in central nervous system aspergillosis, using voriconazole treatment by Stefan Schwartz, Markus Ruhnke, Patricia Ribaud, Lawrence Corey,
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 3 Molecular subgroups of glioblastoma,

Figure 3 Molecular subgroups of glioblastoma,
WT G>A G>C G>T (n = 93) (n = 21) (n = 10) (n = 51)

WT G>A G>C G>T (n = 93) (n = 21) (n = 10) (n = 51)
Focus on central nervous system neoplasia

Focus on central nervous system neoplasia
Volume 66, Issue 2, Pages (August 2014)

Volume 66, Issue 2, Pages (August 2014)
Masui_suppl Fig1 TMab-6 sc-7215 (0.5 μg/mL) (1.0 μg/mL) Case: Astro_2

Masui_suppl Fig1 TMab-6 sc-7215 (0.5 μg/mL) (1.0 μg/mL) Case: Astro_2

Similar presentations

Ads by Google